全文获取类型
收费全文 | 257333篇 |
免费 | 8850篇 |
国内免费 | 6082篇 |
专业分类
耳鼻咽喉 | 2056篇 |
儿科学 | 7416篇 |
妇产科学 | 3808篇 |
基础医学 | 25049篇 |
口腔科学 | 2731篇 |
临床医学 | 22876篇 |
内科学 | 41706篇 |
皮肤病学 | 1429篇 |
神经病学 | 20395篇 |
特种医学 | 11984篇 |
外国民族医学 | 44篇 |
外科学 | 37825篇 |
综合类 | 18338篇 |
现状与发展 | 17篇 |
一般理论 | 3篇 |
预防医学 | 23812篇 |
眼科学 | 5017篇 |
药学 | 18630篇 |
72篇 | |
中国医学 | 6290篇 |
肿瘤学 | 22767篇 |
出版年
2024年 | 320篇 |
2023年 | 1188篇 |
2022年 | 3218篇 |
2021年 | 4015篇 |
2020年 | 3243篇 |
2019年 | 2584篇 |
2018年 | 24433篇 |
2017年 | 19874篇 |
2016年 | 21824篇 |
2015年 | 4830篇 |
2014年 | 5673篇 |
2013年 | 5377篇 |
2012年 | 13703篇 |
2011年 | 27865篇 |
2010年 | 23652篇 |
2009年 | 15462篇 |
2008年 | 24084篇 |
2007年 | 26115篇 |
2006年 | 4991篇 |
2005年 | 6318篇 |
2004年 | 6253篇 |
2003年 | 7217篇 |
2002年 | 4893篇 |
2001年 | 2315篇 |
2000年 | 2256篇 |
1999年 | 1881篇 |
1998年 | 1189篇 |
1997年 | 1159篇 |
1996年 | 836篇 |
1995年 | 807篇 |
1994年 | 636篇 |
1993年 | 449篇 |
1992年 | 499篇 |
1991年 | 517篇 |
1990年 | 458篇 |
1989年 | 330篇 |
1988年 | 309篇 |
1987年 | 275篇 |
1986年 | 176篇 |
1985年 | 153篇 |
1984年 | 99篇 |
1983年 | 69篇 |
1982年 | 59篇 |
1981年 | 41篇 |
1980年 | 65篇 |
1979年 | 42篇 |
1938年 | 60篇 |
1934年 | 31篇 |
1932年 | 56篇 |
1930年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
文题释义:肱骨近端骨折:肱骨近端包括肱骨头及大结节、小结节,中老年人骨质疏松及低能量损伤可导致肱骨近端骨折。
同种异体腓骨:取自于人体异体,经过加工处理,去除其免疫原性,保留其骨性结构,可用于移植修复骨缺损,起到支撑作用。
背景:肱骨近端骨折是临床常见骨折,但对肱骨近端内侧柱缺乏支撑的骨折目前仍是治疗难点,并发症常见,失败率较高。
目的:比较解剖锁定钢板联合同种异体腓骨与单纯解剖锁定钢板治疗肱骨近端骨折的疗效。
方法:使用计算机检索PubMed、Embase、Cochrane Library、Google Scholar、中国知网、万方、维普数据库,检索时间均从建库到2020年2月。检索国内外关于对比研究解剖锁定钢板联合同种异体腓骨与单纯解剖锁定钢板治疗肱骨近端骨折疗效的文献。2名研究员根据纳入和排除标准分别独立筛选文献,提取数据,评估文献中的偏倚风险。纳入12篇相关文献使用RevMan 5.2软件将以下指标进行Meta分析,包括影像学数据、功能评分和并发症。结果与结论:①通过文献检索、根据纳入和排除标准,12篇文献纳入研究,其中11篇为回顾性队列研究,1篇为随机对照研究;纳入研究文献质量高,但GRADE证据质量级别较低。②共纳入958例患者,其中解剖锁定钢板联合同种异体腓骨组411例,单纯解剖锁定钢板组547例;③Meta分析结果显示,解剖锁定钢板联合同种异体腓骨组术后1年肱骨头高度差值(MD=-2.40,95%CI:-2.49至-2.31)、颈干角差值(MD= -6.14,95%CI:-6.62至-5.67)、目测类比评分(MD=-0.22,95%CI:-0.35至-0.08)、肩关节功能评分(MD=4.12,95%CI:2.18-6.06),上肢伤残评分(MD=-10.32,95%CI:-13.44至-7.19)、术后2年的目测类比评分(MD=-0.37,95%CI:-0.55至-0.19)、肩关节功能评分(MD=5.07,95%CI:2.86-7.27)、总体并发症(OR=0.31,95%CI:0.20-0.48)及肱骨头螺钉切出(OR=0.25,95%CI:0.11-0.55)均明显优于单纯解剖锁定钢板组(P < 0.05),肱骨头坏死(OR=0.94,95%CI:0.47-1.88),两组间差异无显著性意义(P > 0.05);④因此,较弱的证据提示,肱骨近端解剖锁定钢板联合同种异体腓骨治疗肱骨近端骨折的短期疗效优于解剖锁定钢板,可减少并发症的发生,促进功能恢复。ORCID: 0000-0002-8486-3932(阳运康)
中国组织工程研究杂志出版内容重点:人工关节;骨植入物;脊柱;骨折;内固定;数字化骨科;组织工程 相似文献
12.
13.
N. S. Hari Narayana Moorthy Sergio F. Sousa Maria J. Ramos Pedro A. Fernandes 《Medicinal chemistry research》2016,25(7):1340-1357
Farnesyltransferase (FTase) is one of the prenyltransferase family enzymes that catalyse the transfer of 15-membered isoprenoid (farnesyl) moiety to the cysteine of CAAX motif-containing proteins including Rho and Ras family of G proteins. Inhibitors of FTase act as drugs for cancer, malaria, progeria and other diseases. In the present investigation, we have developed two structure-based pharmacophore models from protein–ligand complex (3E33 and 3E37) obtained from the protein data bank. Molecular dynamics (MD) simulations were performed on the complexes, and different conformers of the same complex were generated. These conformers were undergone protein–ligand interaction fingerprint (PLIF) analysis, and the fingerprint bits have been used for structure-based pharmacophore model development. The PLIF results showed that Lys164, Tyr166, TrpB106 and TyrB361 are the major interacting residues in both the complexes. The RMSD and RMSF analyses on the MD-simulated systems showed that the absence of FPP in the complex 3E37 has significant effect in the conformational changes of the ligands. During this conformational change, some interactions between the protein and the ligands are lost, but regained after some simulations (after 2 ns). The structure-based pharmacophore models showed that the hydrophobic and acceptor contours are predominantly present in the models. The pharmacophore models were validated using reference compounds, which significantly identified as HITs with smaller RMSD values. The developed structure-based pharmacophore models are significant, and the methodology used in this study is novel from the existing methods (the original X-ray crystallographic coordination of the ligands is used for the model building). In our study, along with the original coordination of the ligand, different conformers of the same complex (protein–ligand) are used. It concluded that the developed methodology is significant for the virtual screening of novel molecules on different targets. 相似文献
14.
An-feng TAO Zheng-hao XU Cheng-hao WU Yi WANG Wei-wei HOU Shi-hong ZHANG Zhong CHEN 《浙江大学学报(医学版)》2015,44(3):315
目的观察比较不同脉冲波形的低频率电刺激对海马电点燃癫痫模型小鼠的作用差异。方法采用电点燃刺激法建立小鼠癫痫模型, 观察正弦波、单相方波、双相方波低频率电刺激对模型小鼠癫痫行为发作及后放电持续时间的影响, 并比较不同时间点给予正弦波低频率电刺激的抗癫痫作用。结果与对照组比较, 正弦波低频率电刺激30 s能降低小鼠海马电点燃癫痫发作等级(2.85 ± 0.27 vs 4.75 ±0.12, P < 0.05)、减少大发作概率(53.6% vs 96.5%, P < 0.01) 和缩短后放电持续时间[(16.22 ± 1.69) s vs (30.29 ± 1.12) s, P < 0.01], 而单相方波和双相方波低频率电刺激30 s没有明显的抗癫痫作用。常用的单相方波低频率电刺激15 min能降低小鼠海马电点燃发作等级(3.58 ± 0.16, P < 0.05)、减少大发作概率(66.7%, P < 0.01);但对海马后放电持续时间及大发作持续时间无影响(均 P>0.05)。此外, 电点燃刺激前预先给予或结束后3 s内给予正弦波低频率电刺激具有明显的抗癫痫作用( P < 0.05或 P < 0.01), 而电点燃刺激结束10 s给予正弦波低频率电刺激则无上述抗癫痫作用。 结论低频率电刺激抗癫痫作用受波形参数的影响, 其中正弦波低频率电刺激能有效抑制小鼠海马电点燃癫痫的发作。 相似文献
15.
To evaluate the anthropometric indexes in subjects with varicocele compared to controls and the incidence of varicocele in different body mass index (BMI) groups for the purpose of exploring the association between varicocele and anthropometric indexes. A comprehensive literature search was conducted by using PubMed, MEDLINE, EMBASE databases and Cochrane Library up to February 2019. A systematic review and meta‐analysis was conducted by STATA, and Newcastle–Ottawa Scale was utilised for assessing risk of bias. Ultimately, 13 articles containing seven case–control studies and six cross‐sectional studies with 1,385,630 subjects were involved in our study. Pooled results demonstrated that varicocele patients had a lower BMI (WMD = ?0.77, 95% CI = ?1.03 to ?0.51) and a higher height than nonvaricocele participants, especially in grade 3 varicocele patients. Subgroup analyses showed that normal BMI individuals had a higher risk of varicocele than obese or overweight individuals and a lower risk than underweight individuals. In conclusion, this study indicates that varicocele patients have a lower BMI and a higher height than nonvaricocele participants. Moreover, men with excess bodyweight have a lower incidence of varicocele compared to normal weight or underweight people. That is to say, high BMI and adiposity protect against varicocele and high BMI is associated with a decreased risk of varicocele. 相似文献
16.
Valerie Iles 《Health care analysis》2016,24(2):105-118
This paper takes a somewhat slant perspective on flourishing and care in the context of suffering, death and dying, arguing that care in this context consists principally of ‘acts of work and courage that enable flourishing’. Starting with the perception that individuals, society and health care professionals have become dulled to death and the process of dying in Western advanced health systems, it suggests that for flourishing to occur, both of these aspects of life need to be faced more directly. The last days of life need to be ‘undulled’. Reflections upon the experiences of the author as carer and daughter in the face of her mother’s experience of death are used as basis for making suggestions about how care systems and professionals might better assist people in dealing with ‘the most grown up thing’ humans ever do, which is to die. 相似文献
17.
18.
目的:探讨miR-26b参与原发性肝细胞肝癌(HCC)侵袭的机制。方法:在细胞培养液中培养人肝细胞系HL-7702和HCC细胞各系Hepb-3、HuH-7、MHCC97-L、MHCC97-H。实时荧光定量PCR法(qRT-PCR)检测miR-26b的表达水平;用miR-26b mimics、miR-26b inhibitors和Notch1-siRNA分别转染HCC细胞;MTT实验检测转染后HCC细胞的活力;采用Western blot检测Notch1受体蛋白表达水平的变化;Transwell小室测定不同处理后的HCC细胞的侵袭能力。结果:人正常肝细胞系HL-7702和HCC细胞系Hepb-3、HuH-7、MHCC97-L、MHCC97-H中的miR-26b相对表达含量随其侵袭和迁移能力的升高而依次下降;抑制miR-26b的表达,Notch1受体蛋白表达明显增高,而此时HCC细胞的侵袭性显著增强;相反,上调miR-26b的表达,Notch1受体蛋白表达明显降低,而HCC细胞侵袭性显著下降;miR-26b可能通过调控Notch1信号通路调节HCC细胞侵袭性。结论:miR-26b通过负调控Notch1信号通路抑制HCC细胞侵袭能力,为HCC侵袭的机制奠定了理论基础,miR-26b可能成为HCC治疗的新靶点。 相似文献
19.
20.
Henry Havel Gregory Finch Pamela Strode Marc Wolfgang Stephen Zale Iulian Bobe Hagop Youssoufian Matthew Peterson Maggie Liu 《The AAPS journal》2016,18(6):1373-1378
Advancing nanomedicines from concept to clinic requires integration of new science with traditional pharmaceutical development. The medical and commercial success of nanomedicines is greatly facilitated when those charged with developing nanomedicines are cognizant of the unique opportunities and technical challenges that these products present. These individuals must also be knowledgeable about the processes of clinical and product development, including regulatory considerations, to maximize the odds for successful product registration. This article outlines these topics with a goal to accelerate the combination of academic innovation with collaborative industrial scientists who understand pharmaceutical development and regulatory approval requirements—only together can they realize the full potential of nanomedicines for patients. 相似文献